BR112021021508A2 - Derivados de 3-amino-4h-benzo[e][1,2,4]tiadiazina 1,1-dióxido como inibidores de mrgx2 - Google Patents
Derivados de 3-amino-4h-benzo[e][1,2,4]tiadiazina 1,1-dióxido como inibidores de mrgx2Info
- Publication number
- BR112021021508A2 BR112021021508A2 BR112021021508A BR112021021508A BR112021021508A2 BR 112021021508 A2 BR112021021508 A2 BR 112021021508A2 BR 112021021508 A BR112021021508 A BR 112021021508A BR 112021021508 A BR112021021508 A BR 112021021508A BR 112021021508 A2 BR112021021508 A2 BR 112021021508A2
- Authority
- BR
- Brazil
- Prior art keywords
- mrgx2
- thiadiazine
- benzo
- inhibitors
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
- C07D285/32—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
derivados de 3-amino-4h-benzo[e][1,2,4]tiadiazina 1,1- dióxido como inibidores de mrgx2. são revelados compostos de fórmula 1, tautômeros destes , e sais farmaceuticamente aceitáveis dos compostos ou tautômeros, em que l, r1, r2, r3, r4 e r5 são definidos no relatório descritivo. essa revelação também está relacionada aos materiais e métodos para a preparação de compostos de fórmula 1, às composições farmacêuticas que os contêm, e ao seu uso para o tratamento de doenças, distúrbios ou condições associadas com mrgx2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962840344P | 2019-04-29 | 2019-04-29 | |
PCT/US2020/030305 WO2020223255A1 (en) | 2019-04-29 | 2020-04-28 | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021021508A2 true BR112021021508A2 (pt) | 2022-03-22 |
Family
ID=70779887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021508A BR112021021508A2 (pt) | 2019-04-29 | 2020-04-28 | Derivados de 3-amino-4h-benzo[e][1,2,4]tiadiazina 1,1-dióxido como inibidores de mrgx2 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20220119361A1 (pt) |
EP (1) | EP3962901A1 (pt) |
JP (1) | JP2022535672A (pt) |
KR (1) | KR20220012244A (pt) |
CN (1) | CN114072393A (pt) |
AR (1) | AR119728A1 (pt) |
AU (1) | AU2020266529A1 (pt) |
BR (1) | BR112021021508A2 (pt) |
CA (1) | CA3137584A1 (pt) |
CL (1) | CL2021002805A1 (pt) |
CO (1) | CO2021014155A2 (pt) |
CR (1) | CR20210544A (pt) |
DO (1) | DOP2021000223A (pt) |
EC (1) | ECSP21080966A (pt) |
IL (1) | IL287521A (pt) |
JO (1) | JOP20210275A1 (pt) |
MA (1) | MA55804A (pt) |
MX (1) | MX2021013135A (pt) |
PE (1) | PE20220425A1 (pt) |
SG (1) | SG11202111717XA (pt) |
TW (1) | TW202106669A (pt) |
WO (1) | WO2020223255A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI782504B (zh) * | 2020-05-08 | 2022-11-01 | 美商美國禮來大藥廠 | (三氟甲基)嘧啶-2-胺化合物 |
WO2022152853A1 (en) * | 2021-01-15 | 2022-07-21 | Glaxosmithkline Intellectual Property Development Limited | Antagonists of mrgx2 |
WO2022152852A1 (en) * | 2021-01-15 | 2022-07-21 | Glaxosmithkline Intellectual Property Development Limited | Antagonists of mrgx2 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US20060217370A1 (en) * | 2005-02-18 | 2006-09-28 | Ethan Burstein | Compounds useful for the treatment and prevention of pain and screening methods therefor |
WO2008052072A2 (en) * | 2006-10-24 | 2008-05-02 | Acadia Pharmaceuticals Inc. | Compounds for the treatment of pain and screening methods therefor |
-
2020
- 2020-04-28 AU AU2020266529A patent/AU2020266529A1/en active Pending
- 2020-04-28 WO PCT/US2020/030305 patent/WO2020223255A1/en active Application Filing
- 2020-04-28 JO JOP/2021/0275A patent/JOP20210275A1/ar unknown
- 2020-04-28 JP JP2021564138A patent/JP2022535672A/ja active Pending
- 2020-04-28 MX MX2021013135A patent/MX2021013135A/es unknown
- 2020-04-28 CR CR20210544A patent/CR20210544A/es unknown
- 2020-04-28 SG SG11202111717XA patent/SG11202111717XA/en unknown
- 2020-04-28 EP EP20727455.6A patent/EP3962901A1/en active Pending
- 2020-04-28 US US17/605,962 patent/US20220119361A1/en active Pending
- 2020-04-28 CA CA3137584A patent/CA3137584A1/en active Pending
- 2020-04-28 MA MA055804A patent/MA55804A/fr unknown
- 2020-04-28 PE PE2021001772A patent/PE20220425A1/es unknown
- 2020-04-28 CN CN202080047972.XA patent/CN114072393A/zh active Pending
- 2020-04-28 TW TW109114154A patent/TW202106669A/zh unknown
- 2020-04-28 BR BR112021021508A patent/BR112021021508A2/pt unknown
- 2020-04-28 KR KR1020217037664A patent/KR20220012244A/ko unknown
- 2020-04-29 AR ARP200101202A patent/AR119728A1/es unknown
-
2021
- 2021-10-22 CO CONC2021/0014155A patent/CO2021014155A2/es unknown
- 2021-10-24 IL IL287521A patent/IL287521A/en unknown
- 2021-10-26 CL CL2021002805A patent/CL2021002805A1/es unknown
- 2021-10-29 DO DO2021000223A patent/DOP2021000223A/es unknown
- 2021-11-15 EC ECSENADI202180966A patent/ECSP21080966A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR119728A1 (es) | 2022-01-05 |
CN114072393A (zh) | 2022-02-18 |
KR20220012244A (ko) | 2022-02-03 |
CA3137584A1 (en) | 2020-11-05 |
WO2020223255A1 (en) | 2020-11-05 |
US20220119361A1 (en) | 2022-04-21 |
CO2021014155A2 (es) | 2021-10-29 |
MA55804A (fr) | 2022-04-06 |
AU2020266529A1 (en) | 2021-12-16 |
ECSP21080966A (es) | 2022-01-31 |
CL2021002805A1 (es) | 2022-07-22 |
MX2021013135A (es) | 2021-11-25 |
DOP2021000223A (es) | 2022-01-16 |
TW202106669A (zh) | 2021-02-16 |
EP3962901A1 (en) | 2022-03-09 |
PE20220425A1 (es) | 2022-03-29 |
JP2022535672A (ja) | 2022-08-10 |
JOP20210275A1 (ar) | 2023-01-30 |
IL287521A (en) | 2021-12-01 |
SG11202111717XA (en) | 2021-11-29 |
CR20210544A (es) | 2022-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021021508A2 (pt) | Derivados de 3-amino-4h-benzo[e][1,2,4]tiadiazina 1,1-dióxido como inibidores de mrgx2 | |
BR112022007783A2 (pt) | Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer | |
BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
BR112018007772A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
BR112016015983A2 (pt) | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica | |
BRPI0910439B8 (pt) | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos | |
BRPI0816064B8 (pt) | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica | |
BR112016016844A2 (pt) | Compostos heterocíclicos | |
BR112012010124A2 (pt) | composto, uso de um animal composto, derivado de cromenona, e, método para o tratamento ou prevenção de um animal de sangue quente tendo tumores que são sensíveis á inibição das enzimas de pi 3-cinase | |
BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
BR112013017779A2 (pt) | derivados de oxazina e seu uso no tratamento de distúrbios neurológicos | |
BR112018069302A2 (pt) | naftiridinas como antagonistas de integrina | |
BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
BR112018007811A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
BRPI0821266B8 (pt) | Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica | |
BR112017027411A2 (pt) | inibidores de nadph oxidase 4 | |
BR112015000386A2 (pt) | derivados de azaindol os quais agem como inibidores de pi3k | |
BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
BR112021022889A8 (pt) | Derivados heterocíclicos fundidos, seus usos, composição farmacêutica e produto compreendendo os mesmos e método para a preparação dos mesmos | |
BR112022004819A2 (pt) | Derivados de piridazin-3(2h)-ona azol-fundidos | |
BR112017022757A2 (pt) | derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap) | |
BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
BR112017013998A2 (pt) | novos derivados de benzimidazol como agentes anti-histamínicos | |
BR112018015191A2 (pt) | compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida |